KAI Pharmaceuticals

About:

KAI Pharmaceuticals discovers and develops novel therapeutics for cardiovascular diseases, kidney diseases and pain.

Website: http://www.kaipharmaceuticals.com

Top Investors: InterWest Partners, Aberdare Ventures, Investor Growth Capital Limited, Intersouth Partners, MDS Capital

Description:

KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.